Rwanda is scheduled to begin mass vaccination of young women against what they say is cervical cancer despite the fact that HPV vaccines have not been proven to prevent cancer; despite the fact that post-vaccination women will still need the same recommended cancer screening that is recommended before vaccination. Is adequate gynecological care available to […]
Human papillomavirus (HPV) type distribution in cervical carcinoma, low-grade, and high-grade squamous intraepithelial lesions in Venezuelan women.
Correnti M, Medina F, Cavazza ME, Rennola A, Avila M, Fernándes A. Abstract OBJECTIVE: Cervical cancer is an important cause of mortality among women in developing countries, especially in the Latin America and Caribbean (LAC) region. Infection with high-risk (HR) human papillomavirus (HPV) has been identified as the primary cause of cervical cancer. The aim […]
CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer
Chatterjee K, Williamson AL, Hoffman M, Dandara C. Division of Medical Virology and Institute of Infectious Disease and Molecular Medicine (IIDMM), University of Cape Town, Cape Town, Republic of South Africa. Abstract Only a small fraction of women infected with human papillomavirus (HPV) progress to cervical cancer pointing to additional risk factors including host genetics […]
SaneVax urges FDA and NCI to establish a reliable HPV genotyping test for virology-based cervical cancer prevention in patient care
By: Norma Erickson 06 November 2010 Last Tuesday, the SaneVax team sent a letter to Dr. Margaret Hamburg, FDA Commissioner, and Dr. Harold E. Varmus, Director of the National Cancer Institute (NCI), requesting the establishment of a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care. […]
- « Previous Page
- 1
- …
- 6
- 7
- 8
